HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
UST
uronyl 2-sulfotransferase
Chromosome 6 · 6q25.1
NCBI Gene: 10090Ensembl: ENSG00000111962.9HGNC: HGNC:17223UniProt: Q9Y2C2
26PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
dermatan sulfate proteoglycan biosynthetic processchondroitin 2-sulfotransferase activity3'-phosphoadenosine 5'-phosphosulfate bindingdermatan 2-sulfotransferase activityatrial fibrillationopen-angle glaucomahemolytic anemiaamyotrophic lateral sclerosis
✦AI Summary

UST (uronyl 2-sulfotransferase) is a sulfotransferase enzyme that catalyzes the transfer of sulfo groups to the 2-OH position of uronyl residues in glycosaminoglycan chains using 3'-phospho-5'-adenylyl sulfate (PAPS) as a sulfate donor 12. The enzyme exhibits substrate specificity, showing high activity toward iduronyl residues in dermatan sulfate and glucuronyl residues in chondroitin sulfate, while displaying minimal activity toward heparin or heparosan derivatives 12. UST localizes to the Golgi membrane where it participates in glycosaminoglycan biosynthesis, specifically contributing to dermatan sulfate and chondroitin sulfate proteoglycan production. This sulfation is critical for the structural and functional properties of extracellular matrix components. Mutations or dysregulation of UST activity would be expected to impact the sulfation patterns of these essential proteoglycans, potentially affecting cell signaling, tissue integrity, and extracellular matrix organization. However, the provided abstracts contain no information regarding UST gene mutations, disease associations, or clinical significance in human pathology, limiting comprehensive assessment of disease relevance and clinical applications.

Sources cited
1
UST catalyzes sulfate transfer to uronyl residues in glycosaminoglycans with activity toward iduronyl residues in dermatan sulfate and glucuronyl residues in chondroitin sulfate
PMID: 10187838
2
UST utilizes PAPS to transfer sulfo groups to 2-OH positions of uronyl residues with substrate specificity for dermatan sulfate and chondroitin sulfate
PMID: 17227754
⚠Limited data available — This gene has 2 indexed publications. Summary and analysis may be incomplete.
Disease Associationsⓘ20
atrial fibrillationOpen Targets
0.36Weak
open-angle glaucomaOpen Targets
0.32Weak
hemolytic anemiaOpen Targets
0.31Weak
amyotrophic lateral sclerosisOpen Targets
0.29Weak
ulcerative colitisOpen Targets
0.28Weak
pneumonitisOpen Targets
0.27Weak
Dupuytren ContractureOpen Targets
0.26Weak
self-injurious ideationOpen Targets
0.25Weak
contact dermatitisOpen Targets
0.24Weak
heart diseaseOpen Targets
0.24Weak
placenta praeviaOpen Targets
0.21Weak
Abnormality of the immune systemOpen Targets
0.21Weak
protozoa infectious diseaseOpen Targets
0.21Weak
Myasthenia gravisOpen Targets
0.20Weak
hypertrophic cardiomyopathyOpen Targets
0.17Weak
enteritisOpen Targets
0.05Suggestive
melanomaOpen Targets
0.05Suggestive
ProptosisOpen Targets
0.04Suggestive
atrial flutterOpen Targets
0.04Suggestive
glaucomaOpen Targets
0.03Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
CHST15Shared pathway100%HS3ST1Protein interaction79%CSGALNACT2Shared pathway67%CHSY3Shared pathway50%DSELShared pathway50%CHPFShared pathway50%
Tissue Expression6 tissues
Brain
100%
Ovary
58%
Lung
27%
Heart
24%
Liver
6%
Bone Marrow
4%
Gene Interaction Network
Click a node to explore
USTCHST15HS3ST1CSGALNACT2CHSY3DSELCHPF
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted · UniProt Q9Y2C2
View on AlphaFold ↗
Constraintⓘ
LOEUFⓘ
0.72LoF Tolerant
pLIⓘ
0.01Tolerant
Observed/Expected LoF0.48 [0.33–0.72]
RankingsWhere UST stands among ~20K protein-coding genes
  • #12,916of 20,598
    Most Researched26
  • #5,544of 17,882
    Most Constrained (LOEUF)0.72
Genes detectedUST
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease.
PMID: 39978335
Cell Metab · 2025
1.00
2
Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease.
PMID: 38112840
Dig Dis Sci · 2024
0.90
3
The Effectiveness of Ultrasound Deep Heat Therapy for Adhesive Capsulitis: A Systematic Review and Meta-Analysis.
PMID: 35162881
Int J Environ Res Public Health · 2022
0.80
4
Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
PMID: 37796648
Am J Gastroenterol · 2024
0.70
5
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis.
PMID: 38685404
J Am Acad Dermatol · 2024
0.60